Provider review, September 2026
This clinic publishes an essay on what the research-use-only label actually does, and it is the sharpest statement of this market's central problem written by anyone selling inside it. It publishes no medication price at all.
LiveNow Longevity does not publish a price today.
LiveNow Longevity also sells 2 compounds this site boards without publishing a price for them: BPC-157 (board ranks no provider) and TB-500 (board ranks no provider).
LiveNow Longevity is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The essay says that a research-use-only label is not a safety warning. It is a legal framing that lets a seller move a product as a laboratory chemical rather than a medication, avoiding the prescription and drug requirements a medication must meet. It says the disclaimer protects the seller and does nothing for the person injecting the product.
It then publishes a table of structural red flags, each described as a sign that a source is operating in the grey market rather than the clinical pathway, and states explicitly that it makes no claim about any specific seller.
It also explains what lawful compounding is, by section, and what that framework requires around sterility, labelling and record-keeping.
Every research-use-only pattern a classifier can carry fires on this page. A classifier that acts on the match rather than the sentence files the most careful writer in the batch alongside the vendors it is warning readers about.
On the tissue-repair peptide's own product page, the seller says the evidence is mostly preclinical, that the compound is not an approved drug, that it is not a first-line treatment and that it is not a substitute for proven care.
That is a seller telling a buyer, on the page selling the thing, that the case for it is weak. It is not common.
It also says the compound is used only under physician supervision as a compounded preparation, and that it should not be bought from an online research-use-only vendor — which is the same argument the essay makes, applied to its own product.
Fourteen dollar amounts appear across the two pages read and all fourteen are the evaluation fee, which sits in the site-wide navigation and therefore repeats on every page.
Its own answer to what the peptide costs is that a buyer starts with a physician evaluation which is applied toward the protocol if they continue — and then no medication figure follows. Even its dedicated cost page prints nothing else.
So a price extractor pointed at this host returns one number fourteen times and that number buys an appointment. No corporate entity is published; identity is a named, board-certified physician whose credentials are published as images.
Live Vital lists one of the deeper peptide menus in this roster — tesamorelin, CJC-1295, ipamorelin, BPC-157, TB-500, GHK-Cu, MOTS-C, glutathione and NAD+ — alongside its GLP-1 line, with coverage across all 50 states.
Read the full Live Vital review
Live Vital is a paid partner; this link may earn a commission. Full disclosure.
Visit Live VitalNo — it is the opposite. Its essay argues that the research-use-only label exists to shift risk to the buyer, and the page fires every grey-market pattern while saying so.
Nothing on the site says. Every figure on both pages read is the evaluation fee, and even the dedicated cost page prints no other number.
The seller says it is applied toward the protocol if the patient continues.
Carefully. Its own product page says the evidence is mostly preclinical, that the compound is not approved, and that it is not a first-line treatment.
No corporate entity appears. A named, board-certified physician stands in for one, with credentials published as enlargeable images.
LiveNow Longevity is not a paid partner; this link may earn a commission if that changes. Full disclosure.